Header Logo

Connection

THOMAS WHEELER to Prostatic Neoplasms

Back to Details
This is a "connection" page, showing publications THOMAS WHEELER has written about Prostatic Neoplasms.
THOMAS WHEELER
Connection Strength
8.766
Prostatic Neoplasms
  1. Editorial Comment. J Urol. 2017 12; 198(6):1323.
    View in: PubMed
    Score: 0.286
  2. Metabolomic signatures of aggressive prostate cancer. Prostate. 2013 Oct; 73(14):1547-60.
    View in: PubMed
    Score: 0.214
  3. Desquamating apoptotic variant of high-grade prostatic intraepithelial neoplasia: a possible precursor of intraductal prostatic carcinoma. Hum Pathol. 2011 Jun; 42(6):892-5.
    View in: PubMed
    Score: 0.181
  4. Ductal adenocarcinoma of the prostate. Hum Pathol. 2011 Apr; 42(4):605-6; author reply 606-7.
    View in: PubMed
    Score: 0.181
  5. Significance of the craniocaudal distribution of cancer in radical prostatectomy specimens. Int J Urol. 2007 Sep; 14(9):817-21.
    View in: PubMed
    Score: 0.143
  6. Prostatic involvement by transitional cell carcinoma in patients with bladder cancer and its prognostic significance. Hum Pathol. 2006 Jun; 37(6):726-34.
    View in: PubMed
    Score: 0.131
  7. Bystin in perineural invasion of prostate cancer. Prostate. 2006 Feb 15; 66(3):266-72.
    View in: PubMed
    Score: 0.129
  8. Radical prostatectomy for carcinoma of the prostate. Mod Pathol. 2004 Mar; 17(3):349-59.
    View in: PubMed
    Score: 0.112
  9. Predictors of extracapsular extension and its radial distance in prostate cancer: implications for prostate IMRT, brachytherapy, and surgery. Cancer J. 2003 Nov-Dec; 9(6):454-60.
    View in: PubMed
    Score: 0.110
  10. Do impalpable stage T1c prostate cancers visible on ultrasound differ from those not visible? J Urol. 2003 Mar; 169(3):964-8.
    View in: PubMed
    Score: 0.105
  11. Low-grade prostate cancer should still be labelled cancer. BJU Int. 2022 12; 130(6):741-743.
    View in: PubMed
    Score: 0.102
  12. Incidence, location, and significance of periprostatic and periseminal vesicle lymph nodes in prostate cancer. Am J Surg Pathol. 2001 Nov; 25(11):1429-32.
    View in: PubMed
    Score: 0.096
  13. ISUP Consensus Definition of Cribriform Pattern Prostate Cancer. Am J Surg Pathol. 2021 08 01; 45(8):1118-1126.
    View in: PubMed
    Score: 0.094
  14. Prognostic significance of the diameter of perineural invasion in radical prostatectomy specimens. Hum Pathol. 2001 Aug; 32(8):828-33.
    View in: PubMed
    Score: 0.094
  15. Primary Gleason pattern as a predictor of disease progression in gleason score 7 prostate cancer: a multivariate analysis of 823 men treated with radical prostatectomy. Am J Surg Pathol. 2001 May; 25(5):657-60.
    View in: PubMed
    Score: 0.092
  16. Cribriform prostate cancer: Morphologic criteria enabling a diagnosis, based on survey of experts. Ann Diagn Pathol. 2021 Jun; 52:151733.
    View in: PubMed
    Score: 0.092
  17. Detection of metastatic prostate cancer using a splice variant-specific reverse transcriptase-polymerase chain reaction assay for human glandular kallikrein. Cancer Res. 2000 Dec 15; 60(24):7142-8.
    View in: PubMed
    Score: 0.090
  18. Intraductal Carcinoma of the Prostate: Pathogenesis and Molecular Perspectives. Eur Urol Focus. 2021 09; 7(5):955-963.
    View in: PubMed
    Score: 0.089
  19. The 2019 International Society of Urological Pathology (ISUP) Consensus Conference on Grading of Prostatic Carcinoma. Am J Surg Pathol. 2020 08; 44(8):e87-e99.
    View in: PubMed
    Score: 0.088
  20. Lymphovascular invasion as a predictor of disease progression in prostate cancer. Am J Surg Pathol. 2000 Jun; 24(6):859-63.
    View in: PubMed
    Score: 0.087
  21. Postatrophic hyperplasia of the prostate: lack of association with prostate cancer. Am J Surg Pathol. 1999 Aug; 23(8):932-6.
    View in: PubMed
    Score: 0.082
  22. Levels of expression of p27KIP1 protein in human prostate and prostate cancer: an immunohistochemical analysis. Mod Pathol. 1999 Aug; 12(8):751-5.
    View in: PubMed
    Score: 0.082
  23. Dataset for the reporting of prostate carcinoma in radical prostatectomy specimens: updated recommendations from the International Collaboration on Cancer Reporting. Virchows Arch. 2019 Sep; 475(3):263-277.
    View in: PubMed
    Score: 0.081
  24. The association of selected pathological features with prostate cancer in a single-needle biopsy accession. Hum Pathol. 1998 Dec; 29(12):1536-8.
    View in: PubMed
    Score: 0.078
  25. Dataset for the reporting of prostate carcinoma in core needle biopsy and transurethral resection and enucleation specimens: recommendations from the International Collaboration on Cancer Reporting (ICCR). Pathology. 2019 Jan; 51(1):11-20.
    View in: PubMed
    Score: 0.078
  26. Patterns of high-grade prostatic intraepithelial neoplasia associated with clinically aggressive prostate cancer. Hum Pathol. 1998 Oct; 29(10):1119-23.
    View in: PubMed
    Score: 0.077
  27. Clinical and pathological significance of the level and extent of capsular invasion in clinical stage T1-2 prostate cancer. Hum Pathol. 1998 Aug; 29(8):856-62.
    View in: PubMed
    Score: 0.076
  28. The significance of intraluminal prostatic crystalloids in benign needle biopsies. Am J Surg Pathol. 1998 Apr; 22(4):446-9.
    View in: PubMed
    Score: 0.074
  29. Distribution and significance of microcalcifications in the neoplastic and nonneoplastic prostate. Arch Pathol Lab Med. 1998 Feb; 122(2):152-5.
    View in: PubMed
    Score: 0.074
  30. Follow-up of Prostatectomy versus Observation for Early Prostate Cancer. N Engl J Med. 2017 07 13; 377(2):132-142.
    View in: PubMed
    Score: 0.071
  31. Influence of irradiation and androgen ablation on prostatic intraepithelial neoplasia. Eur Urol. 1996; 30(2):261-4.
    View in: PubMed
    Score: 0.064
  32. High grade prostatic intraepithelial neoplasia in prostates removed following irradiation failure in the treatment of prostatic adenocarcinoma. Pathol Res Pract. 1995 Sep; 191(9):868-72.
    View in: PubMed
    Score: 0.062
  33. Pelvic lymph node histiocytosis mimicking metastatic prostatic adenocarcinoma: association with hip prostheses. J Urol. 1995 Aug; 154(2 Pt 1):470-3.
    View in: PubMed
    Score: 0.062
  34. Interobserver reproducibility in the diagnosis of prostatic intraepithelial neoplasia. Am J Surg Pathol. 1995 Aug; 19(8):873-86.
    View in: PubMed
    Score: 0.062
  35. Active surveillance for prostate cancer: the role of the pathologist. Pathology. 2015 Jan; 47(1):1-3.
    View in: PubMed
    Score: 0.059
  36. Fresh tissue harvest for research from prostatectomy specimens. Prostate. 1994 Nov; 25(5):274-9.
    View in: PubMed
    Score: 0.059
  37. Consensus statement with recommendations on active surveillance inclusion criteria and definition of progression in men with localized prostate cancer: the critical role of the pathologist. Virchows Arch. 2014 Dec; 465(6):623-8.
    View in: PubMed
    Score: 0.059
  38. DNA ploidy measurements in prostate cancer: differences between image analysis and flow cytometry and clinical implications. Prostate. 1994 Oct; 25(4):189-98.
    View in: PubMed
    Score: 0.058
  39. Intraductal carcinoma of the prostate: interobserver reproducibility survey of 39 urologic pathologists. Ann Diagn Pathol. 2014 Dec; 18(6):333-42.
    View in: PubMed
    Score: 0.058
  40. The critical role of the pathologist in determining eligibility for active surveillance as a management option in patients with prostate cancer: consensus statement with recommendations supported by the College of American Pathologists, International Society of Urological Pathology, Association of Directors of Anatomic and Surgical Pathology, the New Zealand Society of Pathologists, and the Prostate Cancer Foundation. Arch Pathol Lab Med. 2014 Oct; 138(10):1387-405.
    View in: PubMed
    Score: 0.058
  41. Paraganglia of the prostate. Location, frequency, and differentiation from prostatic adenocarcinoma. Am J Surg Pathol. 1994 Apr; 18(4):412-20.
    View in: PubMed
    Score: 0.056
  42. Biological correlates of prostate cancer perineural invasion diameter. Hum Pathol. 2014 Jul; 45(7):1365-9.
    View in: PubMed
    Score: 0.056
  43. Apoptotic index as a biomarker in prostatic intraepithelial neoplasia (PIN) and prostate cancer. J Cell Biochem Suppl. 1994; 19:202-7.
    View in: PubMed
    Score: 0.055
  44. Clinical relevance of the individual prostate cancer focus. Cancer Invest. 1994; 12(4):425-37.
    View in: PubMed
    Score: 0.055
  45. The mechanisms and prognostic significance of seminal vesicle involvement by prostate cancer. Am J Surg Pathol. 1993 Dec; 17(12):1252-61.
    View in: PubMed
    Score: 0.055
  46. Optimization of initial prostate biopsy in clinical practice: sampling, labeling and specimen processing. J Urol. 2013 Jun; 189(6):2039-46.
    View in: PubMed
    Score: 0.052
  47. Dataset for reporting of prostate carcinoma in radical prostatectomy specimens: recommendations from the International Collaboration on Cancer Reporting. Histopathology. 2013 Jan; 62(2):203-18.
    View in: PubMed
    Score: 0.052
  48. Development and clinical validation of a real-time PCR assay for PITX2 DNA methylation to predict prostate-specific antigen recurrence in prostate cancer patients following radical prostatectomy. J Mol Diagn. 2013 Mar; 15(2):270-9.
    View in: PubMed
    Score: 0.052
  49. Intraductal carcinoma of the prostate: precursor or aggressive phenotype of prostate cancer? Prostate. 2013 Mar; 73(4):442-8.
    View in: PubMed
    Score: 0.051
  50. Do adenocarcinomas of the prostate with Gleason score (GS) =6 have the potential to metastasize to lymph nodes? Am J Surg Pathol. 2012 Sep; 36(9):1346-52.
    View in: PubMed
    Score: 0.051
  51. GLIPR1 tumor suppressor gene expressed by adenoviral vector as neoadjuvant intraprostatic injection for localized intermediate or high-risk prostate cancer preceding radical prostatectomy. Clin Cancer Res. 2011 Nov 15; 17(22):7174-82.
    View in: PubMed
    Score: 0.047
  52. Digital quantification of five high-grade prostate cancer patterns, including the cribriform pattern, and their association with adverse outcome. Am J Clin Pathol. 2011 Jul; 136(1):98-107.
    View in: PubMed
    Score: 0.047
  53. Understanding the pathological features of focality, grade and tumour volume of early-stage prostate cancer as a foundation for parenchyma-sparing prostate cancer therapies: active surveillance and focal targeted therapy. BJU Int. 2011 Oct; 108(7):1074-85.
    View in: PubMed
    Score: 0.046
  54. Determining prostate cancer-specific death through quantification of stromogenic carcinoma area in prostatectomy specimens. Am J Pathol. 2011 Jan; 178(1):79-87.
    View in: PubMed
    Score: 0.045
  55. International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 1: specimen handling. Mod Pathol. 2011 Jan; 24(1):6-15.
    View in: PubMed
    Score: 0.044
  56. International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 2: T2 substaging and prostate cancer volume. Mod Pathol. 2011 Jan; 24(1):16-25.
    View in: PubMed
    Score: 0.044
  57. International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 4: seminal vesicles and lymph nodes. Mod Pathol. 2011 Jan; 24(1):39-47.
    View in: PubMed
    Score: 0.044
  58. International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 3: extraprostatic extension, lymphovascular invasion and locally advanced disease. Mod Pathol. 2011 Jan; 24(1):26-38.
    View in: PubMed
    Score: 0.044
  59. International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 5: surgical margins. Mod Pathol. 2011 Jan; 24(1):48-57.
    View in: PubMed
    Score: 0.044
  60. A post-radical-prostatectomy nomogram incorporating new pathological variables and interaction terms for improved prognosis. BJU Int. 2011 Feb; 107(3):389-95.
    View in: PubMed
    Score: 0.044
  61. Multicenter clinical validation of PITX2 methylation as a prostate specific antigen recurrence predictor in patients with post-radical prostatectomy prostate cancer. J Urol. 2010 Jul; 184(1):149-56.
    View in: PubMed
    Score: 0.043
  62. Pathologic basis of the sonographic appearance of the normal and malignant prostate. Urol Clin North Am. 1989 Nov; 16(4):675-91.
    View in: PubMed
    Score: 0.042
  63. Anatomic considerations in carcinoma of the prostate. Urol Clin North Am. 1989 Nov; 16(4):623-34.
    View in: PubMed
    Score: 0.042
  64. Protocol for the examination of specimens from patients with carcinoma of the prostate gland. Arch Pathol Lab Med. 2009 Oct; 133(10):1568-76.
    View in: PubMed
    Score: 0.041
  65. Cytoplasmic accumulation of glycogen synthase kinase-3beta is associated with aggressive clinicopathological features in human prostate cancer. Anticancer Res. 2009 Jun; 29(6):2077-81.
    View in: PubMed
    Score: 0.040
  66. Prognostic value of Akt-1 in human prostate cancer: a computerized quantitative assessment with quantum dot technology. Clin Cancer Res. 2009 May 15; 15(10):3568-73.
    View in: PubMed
    Score: 0.040
  67. Prostate cancer: sextant localization at MR imaging and MR spectroscopic imaging before prostatectomy--results of ACRIN prospective multi-institutional clinicopathologic study. Radiology. 2009 Apr; 251(1):122-33.
    View in: PubMed
    Score: 0.040
  68. Cancer-related axonogenesis and neurogenesis in prostate cancer. Clin Cancer Res. 2008 Dec 01; 14(23):7593-603.
    View in: PubMed
    Score: 0.039
  69. Evaluating localized prostate cancer and identifying candidates for focal therapy. Urology. 2008 Dec; 72(6 Suppl):S12-24.
    View in: PubMed
    Score: 0.039
  70. Bortezomib-mediated inhibition of steroid receptor coactivator-3 degradation leads to activated Akt. Clin Cancer Res. 2008 Nov 15; 14(22):7511-8.
    View in: PubMed
    Score: 0.039
  71. Interobserver variability between expert urologic pathologists for extraprostatic extension and surgical margin status in radical prostatectomy specimens. Am J Surg Pathol. 2008 Oct; 32(10):1503-12.
    View in: PubMed
    Score: 0.039
  72. Grading of invasive cribriform carcinoma on prostate needle biopsy: an interobserver study among experts in genitourinary pathology. Am J Surg Pathol. 2008 Oct; 32(10):1532-9.
    View in: PubMed
    Score: 0.039
  73. Central zone carcinoma of the prostate gland: a distinct tumor type with poor prognostic features. J Urol. 2008 May; 179(5):1762-7; discussion 1767.
    View in: PubMed
    Score: 0.037
  74. Preoperative prediction of unifocal, unilateral, margin-negative, and small volume prostate cancer. Urology. 2008 Jun; 71(6):1166-71.
    View in: PubMed
    Score: 0.037
  75. Local control of prostate cancer with radiotherapy: frequency and prognostic significance of positive results of postirradiation prostate biopsy. NCI Monogr. 1988; (7):95-103.
    View in: PubMed
    Score: 0.037
  76. CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer. Clin Cancer Res. 2007 Dec 01; 13(23):6947-58.
    View in: PubMed
    Score: 0.036
  77. Prognostic significance of location of positive margins in radical prostatectomy specimens. Urology. 2007 Nov; 70(5):965-9.
    View in: PubMed
    Score: 0.036
  78. Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities. J Urol. 2007 Dec; 178(6):2260-7.
    View in: PubMed
    Score: 0.036
  79. Stromogenic prostatic carcinoma pattern (carcinomas with reactive stromal grade 3) in needle biopsies predicts biochemical recurrence-free survival in patients after radical prostatectomy. Hum Pathol. 2007 Nov; 38(11):1611-20.
    View in: PubMed
    Score: 0.036
  80. Correlative evidence that prostate cancer cell-derived caveolin-1 mediates angiogenesis. Hum Pathol. 2007 Nov; 38(11):1688-95.
    View in: PubMed
    Score: 0.036
  81. Improved prediction of prostate cancer recurrence through systems pathology. J Clin Invest. 2007 Jul; 117(7):1876-83.
    View in: PubMed
    Score: 0.035
  82. A proposal on the identification, histologic reporting, and implications of intraductal prostatic carcinoma. Arch Pathol Lab Med. 2007 Jul; 131(7):1103-9.
    View in: PubMed
    Score: 0.035
  83. Forkhead protein FKHR and its phosphorylated form p-FKHR in human prostate cancer. Hum Pathol. 2007 Oct; 38(10):1501-7.
    View in: PubMed
    Score: 0.035
  84. Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis. J Clin Oncol. 2007 Feb 01; 25(4):349-55.
    View in: PubMed
    Score: 0.034
  85. Poorly differentiated prostate cancer treated with radical prostatectomy: long-term outcome and incidence of pathological downgrading. J Urol. 2006 Sep; 176(3):991-5.
    View in: PubMed
    Score: 0.033
  86. Preoperative serum caveolin-1 as a prognostic marker for recurrence in a radical prostatectomy cohort. Clin Cancer Res. 2006 Aug 15; 12(16):4872-5.
    View in: PubMed
    Score: 0.033
  87. Updated protocol for the examination of specimens from patients with carcinomas of the prostate gland. Arch Pathol Lab Med. 2006 Jul; 130(7):936-46.
    View in: PubMed
    Score: 0.033
  88. Stromal antiapoptotic paracrine loop in perineural invasion of prostatic carcinoma. Cancer Res. 2006 May 15; 66(10):5159-64.
    View in: PubMed
    Score: 0.033
  89. Prostate cancer diagnosed after repeat biopsies have a favorable pathological outcome but similar recurrence rate. J Urol. 2006 Mar; 175(3 Pt 1):923-7; discussion 927-8.
    View in: PubMed
    Score: 0.032
  90. Biological response determinants in HSV-tk + ganciclovir gene therapy for prostate cancer. Mol Ther. 2006 Apr; 13(4):716-28.
    View in: PubMed
    Score: 0.032
  91. Biological correlates of p27 compartmental expression in prostate cancer. J Urol. 2006 Feb; 175(2):528-32.
    View in: PubMed
    Score: 0.032
  92. Expanding the therapeutic index of radiation therapy by combining in situ gene therapy in the treatment of prostate cancer. Technol Cancer Res Treat. 2006 Feb; 5(1):23-36.
    View in: PubMed
    Score: 0.032
  93. Mitochondrial DNA G10398A polymorphism and invasive breast cancer in African-American women. Cancer Res. 2006 Feb 01; 66(3):1880; author reply 1880-1.
    View in: PubMed
    Score: 0.032
  94. A cancer DNA phenotype in healthy prostates, conserved in tumors and adjacent normal cells, implies a relationship to carcinogenesis. Proc Natl Acad Sci U S A. 2005 Dec 27; 102(52):19093-6.
    View in: PubMed
    Score: 0.032
  95. Pim-2 upregulation: biological implications associated with disease progression and perinueral invasion in prostate cancer. Prostate. 2005 Nov 01; 65(3):276-86.
    View in: PubMed
    Score: 0.032
  96. Prognostic and predictive factors in prostate cancer: historical perspectives and recent international consensus initiatives. Scand J Urol Nephrol Suppl. 2005 May; (216):8-19.
    View in: PubMed
    Score: 0.030
  97. Prognostic and predictive factors and reporting of prostate carcinoma in prostate needle biopsy specimens. Scand J Urol Nephrol Suppl. 2005 May; (216):20-33.
    View in: PubMed
    Score: 0.030
  98. Prognostic factors and reporting of prostate carcinoma in radical prostatectomy and pelvic lymphadenectomy specimens. Scand J Urol Nephrol Suppl. 2005 May; (216):34-63.
    View in: PubMed
    Score: 0.030
  99. Combined c-Myc and caveolin-1 expression in human prostate carcinoma predicts prostate carcinoma progression. Cancer. 2005 Mar 15; 103(6):1186-94.
    View in: PubMed
    Score: 0.030
  100. Prostatic biopsy after irradiation therapy for prostatic cancer. Urology. 1985 Feb; 25(2 Suppl):39-46.
    View in: PubMed
    Score: 0.030
  101. The emerging role of the PI3-K-Akt pathway in prostate cancer progression. Prostate Cancer Prostatic Dis. 2005; 8(2):108-18.
    View in: PubMed
    Score: 0.030
  102. Decreased stromal expression and increased epithelial expression of WFDC1/ps20 in prostate cancer is associated with reduced recurrence-free survival. Prostate. 2004 Oct 01; 61(2):182-91.
    View in: PubMed
    Score: 0.029
  103. High levels of phosphorylated form of Akt-1 in prostate cancer and non-neoplastic prostate tissues are strong predictors of biochemical recurrence. Clin Cancer Res. 2004 Oct 01; 10(19):6572-8.
    View in: PubMed
    Score: 0.029
  104. Effects of systematic 12-core biopsy on the performance of percent free prostate specific antigen for prostate cancer detection. J Urol. 2004 Sep; 172(3):900-4.
    View in: PubMed
    Score: 0.029
  105. Growth and survival mechanisms associated with perineural invasion in prostate cancer. Cancer Res. 2004 Sep 01; 64(17):6082-90.
    View in: PubMed
    Score: 0.029
  106. Is tumor volume an independent prognostic factor in clinically localized prostate cancer? J Urol. 2004 Aug; 172(2):508-11.
    View in: PubMed
    Score: 0.029
  107. Metastatic cancer DNA phenotype identified in normal tissues surrounding metastasizing prostate carcinomas. Proc Natl Acad Sci U S A. 2004 Aug 03; 101(31):11428-31.
    View in: PubMed
    Score: 0.029
  108. High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate: cancer patients treated with radical prostatectomy. Am J Surg Pathol. 2004 Jul; 28(7):928-34.
    View in: PubMed
    Score: 0.029
  109. Enhanced systemic T-cell activation after in situ gene therapy with radiotherapy in prostate cancer patients. Int J Radiat Oncol Biol Phys. 2004 Jun 01; 59(2):562-71.
    View in: PubMed
    Score: 0.029
  110. Tissue expression of transforming growth factor-beta1 and its receptors: correlation with pathologic features and biochemical progression in patients undergoing radical prostatectomy. Urology. 2004 Jun; 63(6):1191-7.
    View in: PubMed
    Score: 0.029
  111. Predicting the presence and side of extracapsular extension: a nomogram for staging prostate cancer. J Urol. 2004 May; 171(5):1844-9; discussion 1849.
    View in: PubMed
    Score: 0.028
  112. Predictors of prostate cancer after initial negative systematic 12 core biopsy. J Urol. 2004 May; 171(5):1850-4.
    View in: PubMed
    Score: 0.028
  113. Association of preoperative plasma levels of vascular endothelial growth factor and soluble vascular cell adhesion molecule-1 with lymph node status and biochemical progression after radical prostatectomy. J Clin Oncol. 2004 May 01; 22(9):1655-63.
    View in: PubMed
    Score: 0.028
  114. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data. Int J Radiat Oncol Biol Phys. 2004 Apr 01; 58(5):1520-9.
    View in: PubMed
    Score: 0.028
  115. Reduced infiltration of class A scavenger receptor positive antigen-presenting cells is associated with prostate cancer progression. Cancer Res. 2004 Mar 15; 64(6):2076-82.
    View in: PubMed
    Score: 0.028
  116. Association of pre- and postoperative plasma levels of transforming growth factor beta(1) and interleukin 6 and its soluble receptor with prostate cancer progression. Clin Cancer Res. 2004 Mar 15; 10(6):1992-9.
    View in: PubMed
    Score: 0.028
  117. Improved detection of clinically significant, curable prostate cancer with systematic 12-core biopsy. J Urol. 2004 Mar; 171(3):1089-92.
    View in: PubMed
    Score: 0.028
  118. Expression of vascular endothelial growth factor receptor-3 (VEGFR-3) in human prostate. Prostate. 2004 Feb 01; 58(2):193-9.
    View in: PubMed
    Score: 0.028
  119. Assessment of the enhancement in predictive accuracy provided by systematic biopsy in predicting outcome for clinically localized prostate cancer. J Urol. 2004 Jan; 171(1):200-3.
    View in: PubMed
    Score: 0.028
  120. Six additional systematic lateral cores enhance sextant biopsy prediction of pathological features at radical prostatectomy. J Urol. 2004 Jan; 171(1):204-9.
    View in: PubMed
    Score: 0.028
  121. Variations among individual surgeons in the rate of positive surgical margins in radical prostatectomy specimens. J Urol. 2003 Dec; 170(6 Pt 1):2292-5.
    View in: PubMed
    Score: 0.028
  122. Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol. 2003 Nov; 170(5):1792-7.
    View in: PubMed
    Score: 0.027
  123. Reactive stroma as a predictor of biochemical-free recurrence in prostate cancer. Clin Cancer Res. 2003 Oct 15; 9(13):4792-801.
    View in: PubMed
    Score: 0.027
  124. A nomogram to predict seminal vesicle invasion by the extent and location of cancer in systematic biopsy results. J Urol. 2003 Oct; 170(4 Pt 1):1203-8.
    View in: PubMed
    Score: 0.027
  125. The prolyl isomerase Pin1 is a novel prognostic marker in human prostate cancer. Cancer Res. 2003 Oct 01; 63(19):6244-51.
    View in: PubMed
    Score: 0.027
  126. Early postoperative peripheral blood reverse transcription PCR assay for prostate-specific antigen is associated with prostate cancer progression in patients undergoing radical prostatectomy. Cancer Res. 2003 Sep 15; 63(18):5874-8.
    View in: PubMed
    Score: 0.027
  127. Development of an immunoassay for serum caveolin-1: a novel biomarker for prostate cancer. Clin Cancer Res. 2003 Sep 01; 9(10 Pt 1):3653-9.
    View in: PubMed
    Score: 0.027
  128. The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer. J Clin Oncol. 2003 Oct 01; 21(19):3573-9.
    View in: PubMed
    Score: 0.027
  129. Comparison of immunohistochemistry with reverse transcription-PCR for the detection of micrometastatic prostate cancer in lymph nodes. Cancer Res. 2003 Aug 01; 63(15):4662-70.
    View in: PubMed
    Score: 0.027
  130. Expression of neutral amino acid transporter ASCT2 in human prostate. Anticancer Res. 2003 Jul-Aug; 23(4):3413-8.
    View in: PubMed
    Score: 0.027
  131. IMRT for prostate cancer: defining target volume based on correlated pathologic volume of disease. Int J Radiat Oncol Biol Phys. 2003 May 01; 56(1):184-91.
    View in: PubMed
    Score: 0.026
  132. Neural cell adhesion molecule is upregulated in nerves with prostate cancer invasion. Hum Pathol. 2003 May; 34(5):457-61.
    View in: PubMed
    Score: 0.026
  133. Cancer-related changes in prostate DNA as men age and early identification of metastasis in primary prostate tumors. Proc Natl Acad Sci U S A. 2003 Apr 29; 100(9):5401-6.
    View in: PubMed
    Score: 0.026
  134. Detection of clinically significant, occult prostate cancer metastases in lymph nodes using a splice variant-specific rt-PCR assay for human glandular kallikrein. J Clin Oncol. 2003 Apr 01; 21(7):1223-31.
    View in: PubMed
    Score: 0.026
  135. Neuroepithelial interactions in prostate cancer are enhanced in the presence ofprostatic stroma. Urology. 2003 Apr; 61(4):870-5.
    View in: PubMed
    Score: 0.026
  136. Bladder neck involvement in pathological stage pT4 radical prostatectomy specimens is not an independent prognostic factor. J Urol. 2002 Nov; 168(5):2011-5.
    View in: PubMed
    Score: 0.026
  137. Elevated Skp2 protein expression in human prostate cancer: association with loss of the cyclin-dependent kinase inhibitor p27 and PTEN and with reduced recurrence-free survival. Clin Cancer Res. 2002 Nov; 8(11):3419-26.
    View in: PubMed
    Score: 0.026
  138. Preoperative blood reverse transcriptase-PCR assays for prostate-specific antigen and human glandular kallikrein for prediction of prostate cancer progression after radical prostatectomy. Cancer Res. 2002 Oct 15; 62(20):5974-9.
    View in: PubMed
    Score: 0.026
  139. The role of caveolin-1 in androgen insensitive prostate cancer. J Urol. 2002 Oct; 168(4 Pt 1):1589-96.
    View in: PubMed
    Score: 0.025
  140. [The 1992 TNM classification of T2 prostate cancer predicts pathologic stage and prognosis better than the revised 1997 classification]. Nihon Hinyokika Gakkai Zasshi. 2002 Jul; 93(5):595-601.
    View in: PubMed
    Score: 0.025
  141. Analysis of clinical stage T2 prostate cancer: do current subclassifications represent an improvement? J Clin Oncol. 2002 Apr 15; 20(8):2025-30.
    View in: PubMed
    Score: 0.025
  142. Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol. 2002 Feb; 167(2 Pt 1):528-34.
    View in: PubMed
    Score: 0.024
  143. Association of preoperative plasma levels of insulin-like growth factor I and insulin-like growth factor binding proteins-2 and -3 with prostate cancer invasion, progression, and metastasis. J Clin Oncol. 2002 Feb 01; 20(3):833-41.
    View in: PubMed
    Score: 0.024
  144. Combining radiotherapy with gene therapy (from the bench to the bedside): a novel treatment strategy for prostate cancer. Oncologist. 2002; 7(5):458-66.
    View in: PubMed
    Score: 0.024
  145. Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis. Urology. 2001 Dec; 58(6):1008-15.
    View in: PubMed
    Score: 0.024
  146. Phase I/II trial evaluating combined radiotherapy and in situ gene therapy with or without hormonal therapy in the treatment of prostate cancer--a preliminary report. Int J Radiat Oncol Biol Phys. 2001 Nov 01; 51(3):605-13.
    View in: PubMed
    Score: 0.024
  147. Prostate-specific antigen response and systemic T cell activation after in situ gene therapy in prostate cancer patients failing radiotherapy. Hum Gene Ther. 2001 Nov 01; 12(16):1955-67.
    View in: PubMed
    Score: 0.024
  148. In vitro dorsal root ganglia and human prostate cell line interaction: redefining perineural invasion in prostate cancer. Prostate. 2001 Nov 01; 49(3):213-23.
    View in: PubMed
    Score: 0.024
  149. Age-related radical-induced DNA damage is linked to prostate cancer. Cancer Res. 2001 Aug 15; 61(16):6025-8.
    View in: PubMed
    Score: 0.024
  150. Alterations in lipoxygenase and cyclooxygenase-2 catalytic activity and mRNA expression in prostate carcinoma. Neoplasia. 2001 Jul-Aug; 3(4):287-303.
    View in: PubMed
    Score: 0.023
  151. Preoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy. J Clin Oncol. 2001 Jun 01; 19(11):2856-64.
    View in: PubMed
    Score: 0.023
  152. Optimal combinations of systematic sextant and laterally directed biopsies for the detection of prostate cancer. J Urol. 2001 May; 165(5):1554-9.
    View in: PubMed
    Score: 0.023
  153. In situ gene therapy for prostate cancer: immunomodulatory approaches. Expert Opin Biol Ther. 2001 May; 1(3):481-95.
    View in: PubMed
    Score: 0.023
  154. Prediction of response to salvage radiation therapy in patients with prostate cancer recurrence after radical prostatectomy. J Clin Oncol. 2001 Feb 15; 19(4):1030-9.
    View in: PubMed
    Score: 0.023
  155. 15S-Hydroxyeicosatetraenoic acid activates peroxisome proliferator-activated receptor gamma and inhibits proliferation in PC3 prostate carcinoma cells. Cancer Res. 2001 Jan 15; 61(2):497-503.
    View in: PubMed
    Score: 0.023
  156. Leptin and prostate cancer. Prostate. 2001 Jan 01; 46(1):62-7.
    View in: PubMed
    Score: 0.023
  157. Interobserver reproducibility of Gleason grading of prostatic carcinoma: urologic pathologists. Hum Pathol. 2001 Jan; 32(1):74-80.
    View in: PubMed
    Score: 0.023
  158. Reduced infiltration of tumor-associated macrophages in human prostate cancer: association with cancer progression. Cancer Res. 2000 Oct 15; 60(20):5857-61.
    View in: PubMed
    Score: 0.022
  159. Correlation of preoperative plasma IGF-I levels with pathologic parameters and progression in patients undergoing radical prostatectomy. Urology. 2000 Sep 01; 56(3):423-9.
    View in: PubMed
    Score: 0.022
  160. Elevated caveolin-1 levels in African-American versus white-American prostate cancer. Clin Cancer Res. 2000 Sep; 6(9):3430-3.
    View in: PubMed
    Score: 0.022
  161. Cytopathic effect of in situ gene therapy in prostate cancer. Hum Pathol. 2000 Jul; 31(7):866-70.
    View in: PubMed
    Score: 0.022
  162. Induction of human Cdc37 in prostate cancer correlates with the ability of targeted Cdc37 expression to promote prostatic hyperplasia. Oncogene. 2000 Apr 27; 19(18):2186-93.
    View in: PubMed
    Score: 0.021
  163. A precursor form of prostate-specific antigen is more highly elevated in prostate cancer compared with benign transition zone prostate tissue. Cancer Res. 2000 Feb 01; 60(3):756-9.
    View in: PubMed
    Score: 0.021
  164. Differential expression of nuclear retinoid receptors in normal and malignant prostates. J Clin Oncol. 2000 Jan; 18(1):116-21.
    View in: PubMed
    Score: 0.021
  165. Caveolin-1 expression in clinically confined human prostate cancer: a novel prognostic marker. Cancer Res. 1999 Nov 15; 59(22):5719-23.
    View in: PubMed
    Score: 0.021
  166. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol. 1999 May; 17(5):1499-507.
    View in: PubMed
    Score: 0.020
  167. In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial. Hum Gene Ther. 1999 May 01; 10(7):1239-49.
    View in: PubMed
    Score: 0.020
  168. Pathological features and prognostic significance of prostate cancer in the apical section determined by whole mount histology. J Urol. 1999 Feb; 161(2):500-4.
    View in: PubMed
    Score: 0.020
  169. Interposition of sural nerve restores function of cavernous nerves resected during radical prostatectomy. J Urol. 1999 Jan; 161(1):188-92.
    View in: PubMed
    Score: 0.020
  170. Elastic moduli of breast and prostate tissues under compression. Ultrason Imaging. 1998 Oct; 20(4):260-74.
    View in: PubMed
    Score: 0.019
  171. Elevated expression of caveolin is associated with prostate and breast cancer. Clin Cancer Res. 1998 Aug; 4(8):1873-80.
    View in: PubMed
    Score: 0.019
  172. Quantitative immunohistochemical analysis of insulin-like growth factor binding protein-3 in human prostatic adenocarcinoma: a prognostic study. J Urol. 1998 Jun; 159(6):2220-5.
    View in: PubMed
    Score: 0.019
  173. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst. 1998 May 20; 90(10):766-71.
    View in: PubMed
    Score: 0.019
  174. Reduced lysyl oxidase messenger RNA levels in experimental and human prostate cancer. Cancer Res. 1998 Mar 15; 58(6):1285-90.
    View in: PubMed
    Score: 0.019
  175. Assessment of the biologic markers p53, Ki-67, and apoptotic index as predictive indicators of prostate carcinoma recurrence after surgery. Cancer. 1998 Jan 01; 82(1):168-75.
    View in: PubMed
    Score: 0.018
  176. Primary human prostate cancer cells harboring p53 mutations are clonally expanded in metastases. Clin Cancer Res. 1997 Aug; 3(8):1389-97.
    View in: PubMed
    Score: 0.018
  177. Hazard rates for progression after radical prostatectomy for clinically localized prostate cancer. Urology. 1997 Jul; 50(1):93-9.
    View in: PubMed
    Score: 0.018
  178. Has there been a recent shift in the pathological features and prognosis of patients treated with radical prostatectomy? J Urol. 1997 Jun; 157(6):2212-8.
    View in: PubMed
    Score: 0.018
  179. Evaluation of a nomogram used to predict the pathologic stage of clinically localized prostate carcinoma. Cancer. 1997 Feb 01; 79(3):528-37.
    View in: PubMed
    Score: 0.017
  180. Perineural invasion of prostate carcinoma cells is associated with reduced apoptotic index. Cancer. 1996 Sep 15; 78(6):1267-71.
    View in: PubMed
    Score: 0.017
  181. Distinguishing clinically important from unimportant prostate cancers before treatment: value of systematic biopsies. J Urol. 1996 Sep; 156(3):1059-63.
    View in: PubMed
    Score: 0.017
  182. Staging and reporting of prostate cancer--sampling of the radical prostatectomy specimen. Cancer. 1996 Jul 15; 78(2):366-8.
    View in: PubMed
    Score: 0.017
  183. Optimized microvessel density analysis improves prediction of cancer stage from prostate needle biopsies. Urology. 1996 Jul; 48(1):47-57.
    View in: PubMed
    Score: 0.016
  184. Reduced levels of transforming growth factor beta receptor type II in human prostate cancer: an immunohistochemical study. Clin Cancer Res. 1996 Apr; 2(4):635-40.
    View in: PubMed
    Score: 0.016
  185. Impalpable prostate cancer: clinicopathological features. Br J Urol. 1996 Mar; 77(3):429-32.
    View in: PubMed
    Score: 0.016
  186. Clustered p53 immunostaining: a novel pattern associated with prostate cancer progression. Clin Cancer Res. 1996 Feb; 2(2):399-401.
    View in: PubMed
    Score: 0.016
  187. Distant metastasis after radical prostatectomy in patients without an elevated serum prostate specific antigen level. Cancer. 1995 Dec 15; 76(12):2530-4.
    View in: PubMed
    Score: 0.016
  188. Prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol. 1995 Nov; 154(5):1818-24.
    View in: PubMed
    Score: 0.016
  189. Association of p53 mutations with metastatic prostate cancer. Clin Cancer Res. 1995 Oct; 1(10):1111-8.
    View in: PubMed
    Score: 0.016
  190. The frequency of apoptosis correlates with the prognosis of Gleason Grade 3 adenocarcinoma of the prostate. Cancer. 1995 Jan 15; 75(2):522-9.
    View in: PubMed
    Score: 0.015
  191. Salvage radical prostatectomy: outcome measured by serum prostate specific antigen levels. J Urol. 1995 Jan; 153(1):104-10.
    View in: PubMed
    Score: 0.015
  192. The pathological features and prognosis of prostate cancer detectable with current diagnostic tests. J Urol. 1994 Nov; 152(5 Pt 2):1714-20.
    View in: PubMed
    Score: 0.015
  193. Can radical prostatectomy alter the progression of poorly differentiated prostate cancer? J Urol. 1994 Nov; 152(5 Pt 2):1843-9.
    View in: PubMed
    Score: 0.015
  194. Frequency of apoptotic bodies positively correlates with Gleason grade in prostate cancer. Hum Pathol. 1994 Aug; 25(8):797-801.
    View in: PubMed
    Score: 0.014
  195. The New American Joint Committee on Cancer and International Union Against Cancer TNM classification of prostate cancer. Clinicopathologic correlations. Cancer. 1994 Jul 01; 74(1):104-14.
    View in: PubMed
    Score: 0.014
  196. Detection of microscopic extracapsular extension prior to radical prostatectomy for clinically localized prostate cancer. Br J Urol. 1994 Jul; 74(1):72-9.
    View in: PubMed
    Score: 0.014
  197. Prostate specific antigen and gleason grade: an immunohistochemical study of prostate cancer. J Urol. 1994 Jun; 151(6):1558-64.
    View in: PubMed
    Score: 0.014
  198. Some small prostate cancers are nondiploid by nuclear image analysis: correlation of deoxyribonucleic acid ploidy status and pathological features. J Urol. 1994 May; 151(5):1301-7.
    View in: PubMed
    Score: 0.014
  199. The most promising surrogate endpoint biomarkers for screening candidate chemopreventive compounds for prostatic adenocarcinoma in short-term phase II clinical trials. J Cell Biochem Suppl. 1994; 19:283-9.
    View in: PubMed
    Score: 0.014
  200. Heterogeneity of prostate cancer in radical prostatectomy specimens. Urology. 1994 Jan; 43(1):60-6; discussion 66-7.
    View in: PubMed
    Score: 0.014
  201. Ultrasonic detection of non-palpable seminal vesicle invasion: a clinicopathological study. Br J Urol. 1993 Nov; 72(5 Pt 2):799-808.
    View in: PubMed
    Score: 0.014
  202. Comparison of the pathologic features and DNA ploidy value of prostate cancers detectable by sonography and by palpation. Prostate. 1993; 23(4):271-81.
    View in: PubMed
    Score: 0.013
  203. Sonographic monitoring of prostate cancer after definitive radiotherapy. Urology. 1992 Sep; 40(3):230-6.
    View in: PubMed
    Score: 0.013
  204. Frequency and location of extracapsular extension and positive surgical margins in radical prostatectomy specimens. J Urol. 1992 Aug; 148(2 Pt 1):331-7.
    View in: PubMed
    Score: 0.013
  205. Detection of residual prostate cancer after radiotherapy by sonographically guided needle biopsy. Urology. 1992 Apr; 39(4):358-63.
    View in: PubMed
    Score: 0.012
  206. Unusual hyperechoic appearance of prostate cancer on transrectal ultrasonography. Br J Urol. 1992 Feb; 69(2):169-74.
    View in: PubMed
    Score: 0.012
  207. Relationship between clinical stage and histological zone of origin in early prostate cancer: morphometric analysis. Br J Urol. 1991 Nov; 68(5):499-509.
    View in: PubMed
    Score: 0.012
  208. A comparison of the morphological features of cancer arising in the transition zone and in the peripheral zone of the prostate. J Urol. 1991 Oct; 146(4):1069-76.
    View in: PubMed
    Score: 0.012
  209. DNA ploidy by image analysis of individual foci of prostate cancer: a preliminary report. Cancer Res. 1991 Aug 01; 51(15):4084-9.
    View in: PubMed
    Score: 0.012
  210. Transrectal ultrasonography in stage A prostate cancer: detection of residual tumor after transurethral resection of prostate. J Urol. 1991 Aug; 146(2):366-71.
    View in: PubMed
    Score: 0.012
  211. The sonographic appearance of irradiated prostate cancer. Br J Urol. 1991 Aug; 68(2):172-7.
    View in: PubMed
    Score: 0.012
  212. The distribution of residual cancer in radical prostatectomy specimens in stage A prostate cancer. J Urol. 1991 Feb; 145(2):324-8; discussion 328-9.
    View in: PubMed
    Score: 0.011
  213. Staging of prostate cancer. Value of ultrasonography. Urol Clin North Am. 1989 Nov; 16(4):713-34.
    View in: PubMed
    Score: 0.010
  214. Ultrasonographic changes in the normal and malignant prostate after definitive radiotherapy. Urol Clin North Am. 1989 Nov; 16(4):741-9.
    View in: PubMed
    Score: 0.010
  215. The appearance of prostate cancer on transrectal ultrasonography: correlation of imaging and pathological examinations. J Urol. 1989 Jul; 142(1):76-82.
    View in: PubMed
    Score: 0.010
  216. Salvage radical prostatectomy for radiorecurrent adenocarcinoma of the prostate. J Urol. 1988 Sep; 140(3):544-9.
    View in: PubMed
    Score: 0.010
  217. Age-related DNA methylation changes in normal human prostate tissues. Clin Cancer Res. 2007 Jul 01; 13(13):3796-802.
    View in: PubMed
    Score: 0.009
  218. The prognostic significance of post-irradiation biopsy results in patients with prostatic cancer. J Urol. 1986 Mar; 135(3):510-6.
    View in: PubMed
    Score: 0.008
  219. Correlation of preoperative levels of IGF-I and IGFBP-3 with pathologic parameters and clinical outcome in patients with bladder cancer. Urology. 2003 Feb; 61(2):359-64.
    View in: PubMed
    Score: 0.007
  220. Verumontanum mucosal gland hyperplasia in prostatic needle biopsy specimens. A mimic of low grade prostatic adenocarcinoma. Am J Clin Pathol. 1995 Dec; 104(6):620-6.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.